40021
document
The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X . BACKGROUND Free radical-mediated oxidative stress has been implicated in the etiopathogenesis of several disorders . The aim of this study was to elucidate the effect of treatment with nebivolol on the metabolic state of oxidative stress , and antioxidant status markers in patients with cardiac syndrome-X ( CSX ) , additionally , to compare with the effect of metoprolol treatment . METHODS Thirty patients , 17 female and 13 male , with CSX were enrolled in the study . Nebivolol ( 5 mg/day ) or metoprolol ( 50 mg/day ) was administrated for 12 weeks . Twelve hour fasting blood samples , taken at the initiation and on the third month of therapy , were analyzed for the levels of malondialdehyde ( MDA ) , nitrite+nitrate ( NOx ) , and the activity of myeloperoxidase ( MPO ) , superoxide dismutase ( SOD ) . No patient presented additional risk factors for increased reactive oxygen species levels . RESULTS Compared with sixteen control participants , patients with CSX had significantly higher activity of MPO and levels of MDA , but significantly lower SOD activity and levels of NOx before treatment . After treatment , MPO activity and MDA levels were significantly reduced ; SOD activity and NOx levels were significantly increased with nebivolol but remained unchanged with metoprolol . CONCLUSION We have shown that patients with CSX who taken nebivolol have lower serum MPO activity , levels of MDA and higher serum SOD activity , NOx levels when compared with metoprolol treatment . Exercise stress test parameters were also ameliorated in patients who had taken nebivolol in contrast to metoprolol . Nebivolol treatment may be a novel treatment strategy in cases with CSX in the future .
40022
Intervention_Pharmacological
nebivolol treatment
40023
Intervention_Pharmacological
nebivolol
40024
Intervention_Pharmacological
metoprolol treatment
40025
Intervention_Pharmacological
Nebivolol
40026
Intervention_Pharmacological
metoprolol
40027
Intervention_Pharmacological
nebivolol
40028
Intervention_Pharmacological
metoprolol
40029
Intervention_Pharmacological
nebivolol
40030
Intervention_Pharmacological
metoprolol
40031
Intervention_Pharmacological
nebivolol
40032
Intervention_Pharmacological
metoprolol
40033
Intervention_Pharmacological
Nebivolol
40034
Outcome_Physical
levels of malondialdehyde ( MDA
40035
Outcome_Physical
nitrite+nitrate ( NOx )
40036
Outcome_Physical
the activity of myeloperoxidase ( MPO )
40037
Outcome_Physical
superoxide dismutase ( SOD )
40038
Outcome_Physical
activity of MPO
40039
Outcome_Physical
levels of MDA
40040
Outcome_Physical
lower SOD activity
40041
Outcome_Physical
levels of NOx
40042
Outcome_Physical
MPO activity
40043
Outcome_Physical
MDA levels
40044
Outcome_Physical
SOD activity
40045
Outcome_Physical
NOx levels
40046
Outcome_Physical
MPO activity
40047
Outcome_Physical
levels of MDA
40048
Outcome_Physical
serum SOD activity
40049
Outcome_Physical
NOx levels
40050
Participant_Condition
cardiac syndrome-X
40051
Participant_Condition
cardiac syndrome-X ( CSX )
40052
Participant_Sample-size
Thirty
40053
Participant_Sample-size
17
40054
Participant_Sex
female
40055
Participant_Sample-size
13
40056
Participant_Sex
male
40057
Participant_Condition
CSX
40058
Participant_Condition
CSX